Andere Sprachen Chemomab Therapeutics Ltd.

Aktien

A3CMJ9

US16385C1045

CMMB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
0.6399 ^USD	-2.90%		-5.90%	+25.47%

10.04.	Transcript : Chemomab Therapeutics Ltd. - Special Call
07.03.	Chemomab Therapeutics Ltd. meldet Ergebnis für das vierte Quartal und das Gesamtjahr bis zum 31. Dezember 2023	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	24.04.
Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update	24.04.
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis	18.04.
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	02.04.
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024	02.04.
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	25.03.
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis	25.03.
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update	08.03.
Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	07.03.
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference	05.03.
Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases	20.02.
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	14.02.
Chemomab Therapeutics to Participate in Upcoming Investor Conferences	05.02.
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	30.01.
Chemomab Therapeutics Ltd. Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis	30.01.
Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	03.01.
Chemomab Therapeutics Ltd. Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024	03.01.
ADRs Advance, YPF S.A. Climbs 39.9%	20.11.
ADRs Advance, Missfresh Ltd. Climbs 23.3%	17.11.
Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis	17.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Chemomab Therapeutics Ltd.

Aktien

A3CMJ9

US16385C1045

CMMB

Andere Sprachen

Filter